A plethora of proposals are currently under consideration to wring resources out of the pharmaceutical industry, but no amount of money extracted from the life sciences sector can right-size the fundamental imbalance between the federal government’s financial obligations and taxpayers resources to finance those promises.
An inside look at how CEO Yuval Cohen communicates and interacts with employees at Corbus Pharmaceuticals, and how all of that affects the company’s culture.
The life sciences industry in Virginia has been growing rapidly during the past few years, and the state is continuing to attract all facets of companies through its tax credits and research funding.
“Looking back on my 25 years in academic medical research, I can’t think of a single learning experience that equipped me for the world of entrepreneurship, running a public company, or interacting with the capital markets.”
The career path of Orchard Therapeutics’ CEO Mark Rothera provides insight into how the executive came to be a champion of rare disease drug development.
Mark Rothera spent the majority of his career working for U.S.-based biopharmas. So, when he had the opportunity to work in his home country and preferred therapeutic area, he pursued it relentlessly.
You might know Richard Pops is one of the longest tenured CEOs in biopharma, but here are six things perhaps you didn’t know about the chairman of Alkermes.
